Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gene therapy -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (116)	8/4/1999 6:50:00 AM
From: SnowShredder	Respond to of 319

Hi Mike, Sounds like a great meeting, Thanks for the program link. Best of luck, Where'd He Go?

To: Mike McFarland who wrote (116)	8/4/1999 1:01:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 319

Lentiviral vectors for gene therapy, from last week's Science: sciencemag.org

To: Mike McFarland who wrote (116)	8/4/1999 4:31:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 319

No sweat...I do enjoy surfin around--the two speakers that naturally caught me eye: James M. Wilson , University of Pennsylvania AAV for Inherited and Metabolic Diseases Tim Clackson , ARIAD Pharmaceuticals, Inc. Regulating Gene and Cell Therapies Using Small-Molecule Dimerizers CEGE has been strong of late, I'd told myself I was going to buy it as it moved back up through $5...oh well, now at $6 and looking strong. If AAV is supposed to be the vector of choice like I keep seeing, then I'll have wished I'd spread my account between Ariad and CEGE-- Richard O. Snyder , Cell Genesys Inc In vivo AAV-Mediated Gene Delivery Finding these websites with no abstracts might not be especially useful...but at least it gives out a few names from which to do the Pubmed thing